[go: up one dir, main page]

WO2013056684A3 - Dérivé de thiazole en tant qu'inhibiteur de la dhodh et son utilisation - Google Patents

Dérivé de thiazole en tant qu'inhibiteur de la dhodh et son utilisation Download PDF

Info

Publication number
WO2013056684A3
WO2013056684A3 PCT/CN2012/086816 CN2012086816W WO2013056684A3 WO 2013056684 A3 WO2013056684 A3 WO 2013056684A3 CN 2012086816 W CN2012086816 W CN 2012086816W WO 2013056684 A3 WO2013056684 A3 WO 2013056684A3
Authority
WO
WIPO (PCT)
Prior art keywords
thiazole derivative
dhodh inhibitor
dhodh
inhibitor
psoriasis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2012/086816
Other languages
English (en)
Chinese (zh)
Other versions
WO2013056684A2 (fr
Inventor
赵振江
黄瑾
李洪林
徐玉芳
朱丽丽
韩乐
许鸣豪
高瑞
刁妍妍
朱俊生
曹贤文
崔坤强
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
East China University of Science and Technology
Original Assignee
East China University of Science and Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by East China University of Science and Technology filed Critical East China University of Science and Technology
Priority to CN201280048338.3A priority Critical patent/CN103998434B/zh
Publication of WO2013056684A2 publication Critical patent/WO2013056684A2/fr
Publication of WO2013056684A3 publication Critical patent/WO2013056684A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention concerne un dérivé de thiazole, représenté par la formule I, en tant qu'inhibiteur de la DHODH, ainsi que l'utilisation de ce dérivé. Le composé de la présente invention permet le traitement ou la prévention de maladies à médiation DHODH, notamment mais non exclusivement de la polyarthrite rhumatoïde et des maladies auto-immunes telles que tumeurs, rejets de greffe d'organe et psoriasis.
PCT/CN2012/086816 2011-10-18 2012-12-18 Dérivé de thiazole en tant qu'inhibiteur de la dhodh et son utilisation Ceased WO2013056684A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201280048338.3A CN103998434B (zh) 2011-10-18 2012-12-18 作为dhodh抑制剂的噻唑衍生物及其应用

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2011103171249A CN103058949A (zh) 2011-10-18 2011-10-18 做为dhodh抑制剂的噻唑衍生物及其应用
CN201110317124.9 2011-10-18

Publications (2)

Publication Number Publication Date
WO2013056684A2 WO2013056684A2 (fr) 2013-04-25
WO2013056684A3 true WO2013056684A3 (fr) 2013-06-13

Family

ID=48101881

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2012/086816 Ceased WO2013056684A2 (fr) 2011-10-18 2012-12-18 Dérivé de thiazole en tant qu'inhibiteur de la dhodh et son utilisation

Country Status (2)

Country Link
CN (2) CN103058949A (fr)
WO (1) WO2013056684A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10919869B2 (en) 2016-05-17 2021-02-16 East China University Of Science And Technology Thiazole derivative and applications

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104418821A (zh) * 2013-08-22 2015-03-18 四川大学华西医院 2,4位取代的5-(3,4,5-三甲氧基苯基)噻唑衍生物及其制备方法和用途
CN103772315B (zh) * 2014-01-07 2015-10-21 山东汇海医药化工有限公司 一种一步合成4-甲基噻唑-5-甲酸乙酯的方法
CN105777739B (zh) * 2016-02-23 2018-05-08 湖南大学 萘氨基噻唑甲基喹啉酮衍生物及其医药用途
CN107375279B (zh) * 2016-05-17 2022-11-01 华东理工大学 新型噻唑类衍生物在治疗炎性肠病中的应用
WO2018089902A1 (fr) * 2016-11-13 2018-05-17 Apogee Biotechnology Corporation Composés de diaminothiazole, compositions et procédés d'utilisation associés
CN108721283A (zh) * 2017-04-20 2018-11-02 华东理工大学 噻唑衍生物在治疗非淋巴细胞性白血病中的应用
CN110180488B (zh) * 2019-05-07 2020-05-01 东北大学 一种高吸附活性BiOI及其制备方法与应用
JP7663603B2 (ja) 2020-04-24 2025-04-16 バイエル・アクチエンゲゼルシヤフト 免疫活性化のためのｄｇｋｚｅｔａ阻害剤としての置換アミノチアゾール類
CN115701427A (zh) * 2021-08-02 2023-02-10 上海汇伦医药股份有限公司 多取代噻唑衍生物及其在疾病治疗中的应用
CN115724802A (zh) * 2021-09-01 2023-03-03 复旦大学 一种噻唑胺类化合物及其应用
KR102820358B1 (ko) * 2022-08-30 2025-06-12 한국화학연구원 Mkk3 키나아제 억제 화합물을 함유한 천포창 개선 또는 치료용 조성물
CN115448863B (zh) * 2022-10-09 2024-03-26 浙江迪邦化工有限公司 一种3,4-二氯苯基硫脲的连续化制备工艺
WO2025215126A1 (fr) 2024-04-12 2025-10-16 Immunic Ag Synthèse de vidofludimus et de son sel de calcium

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004009017A2 (fr) * 2002-07-18 2004-01-29 Bristol-Myers Squibb Company Modulateurs de recepteurs de glucocorticoides et procede associe
CN1546034A (zh) * 2003-12-08 2004-11-17 南昌弘益科技有限公司 美洛昔康滴丸及其制备方法
CN1617870A (zh) * 2001-09-28 2005-05-18 西克拉塞尔有限公司 作为抗增殖化合物的n－(4－(4－甲基噻唑－5－基)嘧啶－2－基)－n－苯胺
CN101248054A (zh) * 2005-05-24 2008-08-20 雪兰诺实验室有限公司 噻唑衍生物及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3505055A (en) * 1966-12-07 1970-04-07 Uniroyal Inc Method of controlling plant growth with carboxamidothiazoles
EP1983980A4 (fr) * 2006-01-25 2010-05-05 Synta Pharmaceuticals Corp Composes thiazole et thiadiazole destines a des utilisations associees a une inflammation et au système immunitaire
CA2793311C (fr) * 2010-03-17 2019-01-15 Taivex Therapeutics Inc. Modulateurs de l'activite hec1 et procedes associes
EP2547667A1 (fr) * 2010-03-18 2013-01-23 Takeda California, Inc. Procédé pour l'intermédiaire de synthèse du 2-amino-5-fluorothiazole

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1617870A (zh) * 2001-09-28 2005-05-18 西克拉塞尔有限公司 作为抗增殖化合物的n－(4－(4－甲基噻唑－5－基)嘧啶－2－基)－n－苯胺
WO2004009017A2 (fr) * 2002-07-18 2004-01-29 Bristol-Myers Squibb Company Modulateurs de recepteurs de glucocorticoides et procede associe
CN1546034A (zh) * 2003-12-08 2004-11-17 南昌弘益科技有限公司 美洛昔康滴丸及其制备方法
CN101248054A (zh) * 2005-05-24 2008-08-20 雪兰诺实验室有限公司 噻唑衍生物及其应用

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10919869B2 (en) 2016-05-17 2021-02-16 East China University Of Science And Technology Thiazole derivative and applications

Also Published As

Publication number Publication date
CN103058949A (zh) 2013-04-24
WO2013056684A2 (fr) 2013-04-25
CN103998434B (zh) 2016-10-12
CN103998434A (zh) 2014-08-20

Similar Documents

Publication Publication Date Title
WO2013056684A3 (fr) Dérivé de thiazole en tant qu'inhibiteur de la dhodh et son utilisation
WO2014028600A3 (fr) Composés 3-aminocycloalkyl utilisés en tant qu'inhibiteurs de rorgammat et utilisations de ceux-ci
PH12016501972A1 (en) Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors
AU2015207757A8 (en) N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of SHP2
ZA201701299B (en) Glycosidase inhibitors
HK1245236A1 (zh) 具有杀真菌活性的吡啶酰胺化合物
PH12016501941B1 (en) Use of heterocyclic compounds for controlling nematodes
WO2014100764A3 (fr) Procédés d'inhibition de prmt5
MY184978A (en) Pyridin-2-amides useful as cb2 agonists
IL228104A0 (en) 3, 1 oxazolines as 1bace and/or 2bace inhibitors
AU2012214029A8 (en) Rorgammat inhibitors
HK1216176A1 (zh) 用於治疗增殖性和自身免疫疾病的非对称吡咯并苯并二氮杂卓二聚物
MX341456B (es) Amino-quinolinas como inhibidores de cinasa.
MY179412A (en) Pyridine-2-amides useful as cb2 agonists
PH12016501977A1 (en) 2-AMINO-6-METHYL-4,4a,5,6-TETRAHYDROPYRANO[3,4-d][1,3]THIAZIN-8a(8H)-YL-1,3-THIAZOL-4-YL AMIDES
IN2013DE02977A (fr)
WO2012078902A3 (fr) Régulateurs de la protéostasie
MA40076A (fr) Inhibiteurs de syk
SMT202100325T1 (it) Metodi e composizioni per l’inibizione specifica della glicolato ossidasi (hao1) mediante rna a doppio filamento
HK1217492A1 (zh) 作爲刺猬信号通路抑制剂的杂环化合物
JO3318B1 (ar) مثبطات bace
NZ701933A (en) Phenoxyethyl piperidine compounds
PH12016501865A1 (en) Pyridine-2-amides useful as cb2 agonists
EA201790016A1 (ru) АНАЛОГ ПИРИДИНО[1,2-a]ПИРИМИДОНА, ПРИМЕНЯЕМЫЙ В КАЧЕСТВЕ ИНГИБИТОРА PI3K
MA39824A (fr) Composés azole amido-substitués

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12842164

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 12842164

Country of ref document: EP

Kind code of ref document: A2